Since its establishment last year, bioGenous has adhered to its corporate vision of "Leading Pharmaceutical Innovation, Sharing Model Value" and has launched a series of products, including standardized organoid culture kits, whole-process organoid model kits, and high-activity organoid culture growth factors. In order to showcase the unique quality of bioGenous organoid culture products, we are now initiating the "Organoid High-Activity Culture Factor Trial Pack" application activity. We also eagerly look forward to receiving your feedback and valuable suggestions on the products.
Factors for trial in this activity:
▍Stable Stock Production, Small Batch Variability, High Activity
Recombinant Human R-spondin1 20ug, 50 units
▍Addressing Instable Activity of Natural Wnt3a, New Protein Engineering Modification, High Activity
Recombinant Human Wnt/β-Catenin Ligand 10ug, 50 units
Wnt/β-Catenin Ligand Factor Activity Assay and Organoid Culture Function Assay
Application Time
From now until March 9. 2022
Activity Rules
1.Only one unit available for each research group.
2.A few trail products available, and successful applications will be informed of by a specialist.
3.The final interpreyayion of this activity is solely reserved by bioGenous BIOTECH, Inc
Application Process
1.Scan the QR code to follow the WeChat official account
2.Click the menu bar to selecy“伯桢生物”
3.Click “试用装” in the submenu, and fill in the “申领表”
Direct access to the "申领表" by clicking “阅读原文” link
bioGenous current product line is listed below.For detailed information or to explore other products, please feel free to contact us.
bioGenous is a leading one-stop provider of organoid technology products and solutions. The company has been deeply involved in basic organoid research and translational applications for many years. Since 2016, bioGenous has gradually established and perfected a full range of upstream organoid technologies, covering multiple tissue and tumor organoid culture, development and disease modeling, genetic manipulation, efficacy and toxicity evaluation, animal transplantation, multiomics atlas of organoids, organoid precision medicine, automated operations, and more. In 2020, to meet the explosive global demand for CDMO services in organoid technology, bioGenous built a 2,000-square-meter production facility that complies with international GMP standards for biopharmaceuticals. The company is committed to creating a standardized and modular CDMO service platform for basic biological and medical research, drug development, and precision medicine, leading a revolution in biomedical models and advancing human health.
